'Challenging Quarter' For Sanofi As Questions Hang Over Diabetes Franchise
Executive Summary
"A somewhat challenging quarter," was how Sanofi CEO Olivier Brandicourt described the second three months of 2016, but analysts say there were no surprises in the downward trajectory of Sanofi's fortunes. There was also little news on Sanofi's pursuit of Medivation.
You may also be interested in...
Sanofi’s Franchise Defense Sees Biosimilar Insulin Lispro Under EU Review
Sanofi has filed a biosimilar version of Lilly’s antidiabetic Humalog with the EU’s CHMP, and received the all-clear for a new combination of Lantus and lixisenatide, as it tries to address difficulties in its diabetes franchise.
Sanofi’s Franchise Defense Sees Biosimilar Insulin Lispro Under EU Review
Sanofi has filed a biosimilar version of Lilly’s antidiabetic Humalog with the EU’s CHMP, and received the all-clear for a new combination of Lantus and lixisenatide, as it tries to address difficulties in its diabetes franchise.
Shire Looks To Build Around Xiidra, Sanofi Faces Toujeo Challenge, Amgen Downplays Romosozumab Data
Shire, Sanofi and Amgen were among the companies presenting at the Bank of America Merrill Lynch Global Healthcare Conference Sept. 14-16 in London. Here are some key takeaways from those presentations.